Silverback Therapeutics
AcquiredSeattle, US · Founded 2016 · Delaware corporation · 205 employees on LinkedIn · 4 known investors
Founders & leadership
PA
Peter A. ThompsonNamed on SEC filing
Investors · 4
Reported raises · per SEC filings
Form D private placements$139.3M disclosed across 6 of 7 rounds · 2016–2020
▶$85MraisedOct 2020 · 31 investors · BiotechnologyRule 506(b)
▶$85MraisedOct 2020 · 31 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan RootDirector
- Thilo SchroederDirector
- Scott PlatshonDirector
- Laura ShawverExecutive Officer, Director
- Vickie L. CappsDirector
- Robert HershbergDirector
- Saqib IslamDirector
- Peter A. ThompsonDirector
- Offering amount
- $85M
- Amount sold
- $85M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$31.8MraisedMar 2020 · 16 investors · BiotechnologyRule 506(b)
▶$31.8MraisedMar 2020 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter ThompsonExecutive Officer, Director
- Robert HershbergDirector
- Thilo SchroederDirector
- Jonathan RootDirector
- Saqib IslamDirector
- Offering amount
- $78.7M
- Amount sold
- $31.8M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$12.5MraisedSep 2018 · 3 investors · Other TechnologyRule 506(b)
▶$12.5MraisedSep 2018 · 3 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Peter A. ThompsonExecutive Officer, Director
- Robert HershbergDirector
- Saqib IslamDirector
- Offering amount
- $20M
- Amount sold
- $12.5M
- First sale
- Sep 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$3.7KraisedJan 2018 · 1 investors · BiotechnologyRule 506(b)
▶$3.7KraisedJan 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Saqib IslamDirector
- Robert HershbergDirector
- Peter A. ThompsonExecutive Officer, Director
- Offering amount
- $3.7K
- Amount sold
- $3.7K
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$10MraisedFeb 2017 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedFeb 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter A. ThompsonExecutive Officer, Director
- Offering amount
- $60M
- Amount sold
- $10M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$25KofferedNov 2016 · BiotechnologyRule 506(b)
▶$25KofferedNov 2016 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter A. ThompsonExecutive Officer, Director
- Offering amount
- $25K
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$200raisedApr 2016 · 2 investors · BiotechnologyRule 506(b)
▶$200raisedApr 2016 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter A. ThompsonExecutive Officer, Director
- Offering amount
- $200
- Amount sold
- $200
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Silverback Therapeutics's investors?
- Silverback Therapeutics's investors include EcoR1 Capital, Pontifax Venture Capital, RA Capital, US Venture Partners.
- How much funding has Silverback Therapeutics raised?
- Silverback Therapeutics has disclosed $139.3M raised across 6 of its 7 known rounds.
- Where is Silverback Therapeutics headquartered?
- Silverback Therapeutics is headquartered in Seattle, US.